Web Research
Web Research — What the Internet Knows
The Bottom Line from the Web
The financials show a struggling 2026 trough; the web shows why and how risky that trough actually is. CMS notified Elevance on March 2, 2026 of intent to suspend new enrollment in its Medicare Advantage prescription-drug plans starting March 31, prompting a $935M Q1 accrual and at least four shareholder securities-fraud investigations. Yet the same web feed also documents a Q1 2026 EPS beat ($12.58 vs $10.68 consensus, +14%), a guidance raise to $26.75+, a CFO-led leadership reshuffle taking over Carelon, and director-level open-market buying — the bull/bear gap is unusually wide.
What Matters Most
**1. CMS intends to suspend Medicare Advantage drug-plan enrollment — and a $935M accrual was just booked.** On March 2, 2026, CMS notified Elevance of intermediate sanctions that would suspend new enrollment in its Medicare Advantage Part D plans starting March 31, 2026; the stock fell more than 3% on the news. Q1 2026 results then included a **$935M accrual** for potential resubmission of Medicare Advantage risk-adjustment data covering 2015–April 2023. Source: [Reuters, 2026-03-02](https://www.reuters.com/business/healthcare-pharmaceuticals/cms-plans-sanctions-suspending-enrollment-elevances-medicare-advantage-drug-2026-03-02/) and [10-Q via StockTitan](https://www.stocktitan.net/sec-filings/ELV/10-q-elevance-health-inc-quarterly-earnings-report-a31eec23fdd0.html).
**2. At least four securities-fraud investigations have been opened against Elevance.** Kirby McInerney (April 2026), Bragar Eagel & Squire (April 20, 2026), Glancy Prongay & Murray (May 2025), and Bronstein, Gewirtz & Grossman (December 2025) have all opened investigations into possible securities-law violations tied to disclosures around Medicaid cost trends and the CMS sanction. Source: [GlobeNewswire, 2026-04-23](https://www.globenewswire.com/news-release/2026/04/23/3279500/937/en/ELV-INVESTOR-ALERT-Kirby-McInerney-LLP-Investigates-Potential-Claims-Involving-Elevance-Health-Inc.html).
**3. Q1 2026 broke the negative pattern: 14% EPS beat, raised full-year guide.** Reported adjusted EPS of $12.58 vs $10.68 Zacks consensus on revenue of $50.18B; full-year 2026 adjusted EPS guide raised from "at least $25.50" to **"at least $26.75"**, with management reaffirming **at least 12% adjusted EPS growth in 2027** off a $25.75 baseline. Stock rose ~6.7% on the print. Source: [Reuters, 2026-04-22](https://www.reuters.com/business/healthcare-pharmaceuticals/elevance-raises-annual-profit-forecast-betting-cost-control-2026-04-22/) and [Seeking Alpha](https://seekingalpha.com/news/4578111-elevance-health-raises-2026-adjusted-eps-outlook-to-at-least-26_75-while-targeting-at-least).
**4. Major leadership reshuffle: CFO Mark Kaye now also runs Carelon; Pete Haytaian out.** Announced February 26, 2026 and effective May 4, 2026, EVP/President of Carelon Peter Haytaian transitions out (cited family commitments); CFO Mark Kaye expands his remit to oversee Carelon, and Felicia Norwood takes a consolidated Health Benefits role. The combined CFO + segment-president structure is unusual and concentrates execution risk on Kaye. Source: [Elevance press release, 2026-02-26](https://www.elevancehealth.com/newsroom/elevance-health-announces-management-changes-cfo-mark-kaye-to-expand-responsibilities-to-include-carelon-and-felicia-norwood-to-lead-consolidated-health-benefits-organization).
**5. Lost $375M Medicare star-ratings lawsuit (August 2025).** A federal judge in Texas rejected Elevance's challenge to CMS's star-ratings calculation; the company had argued improper rounding cost it at least $375M. Combined with the new Part D sanction, this signals a pattern of unfavorable Medicare regulatory outcomes. Source: [Reuters, 2025-08-19](https://www.reuters.com/legal/litigation/elevance-health-loses-bid-challenge-us-medicare-star-ratings-2025-08-19/).
**6. Insiders are buying, not selling, into the weakness.** A director made an open-market purchase of 3,000 shares on March 6, 2026 (Form 4 code "P"). A Yahoo Finance / Simply Wall St aggregation reported "bullish Elevance Health insiders loaded up on US$3.68m of stock" in the most recent twelve months. Insider ownership remains modest (0.1%–2.72% range across sources, totaling roughly $88M). Source: [StockTitan Form 4, 2026-03-06](https://www.stocktitan.net/sec-filings/ELV/form-4-elevance-health-inc-insider-trading-activity-205db716faad.html), [Yahoo/Simply Wall St](https://finance.yahoo.com/markets/stocks/articles/bullish-elevance-health-insiders-loaded-140008603.html).
**7. Stock is in a deep drawdown — down ~40% from peak.** Closing high of $544.37 on September 3, 2024; recently traded at ~$280–328 (depending on date snapshot). Down 19.4% over the trailing year, ~7% YTD. Trefis notes ELV's historical drawdown beta: in the 2008 GFC it fell 67% vs S&P −57%, and averages a 40% decline through major crashes. Source: [MacroTrends](https://www.macrotrends.net/stocks/charts/ELV/elevance-health/stock-price-history), [Simply Wall St](https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/is-it-time-to-revisit-elevance-health-elv-after-recent-share-1).
**8. Aggressive capital return continues during the trough.** Q1 2026 alone returned $1.5B to shareholders, including 3.7M shares repurchased for $1.1B at an average price of $304.68; ~$5.6B remained authorized. Q2 dividend declared at $1.72/share (annualized ~$6.88, yield roughly 2%). Buyback yield ~1.9%. Source: [Kavout, 2026](https://www.kavout.com/market-lens/what-does-elevance-health-s-q1-2026-performance-signal-for-investors).
**9. Analyst targets cluster in the high-$300s, well below 2024 highs of $600+.** Recent moves (April 2026): Mizuho cut to $350 from $413; Truist to $375 from $390; Jefferies trimmed to $391 from $395 (Buy maintained); JP Morgan raised to $397 from $394 (Overweight); Morgan Stanley equal-weight at $352. Wolfe Research upgraded to Outperform. Implied upside vs current ~$280–328 ranges from negligible to ~40% depending on shop. Marketbeat consensus PT $387.40. Source: [GuruFocus / Benzinga / Marketbeat aggregations](https://www.marketbeat.com/stocks/NYSE/ELV/forecast/).
**10. Carelon (services arm) is the strategic wedge — services revenue grew ~60% in 2025.** Management refined the long-term enterprise margin target to **5%–6%** at Q4 2025 and is positioning Carelon (CarelonRx + Carelon Services) as the diversification engine. CareBridge home-health acquisition (~$2.7B), Paragon Healthcare (Jan 2024), Granular Insurance from Alphabet's Verily (Feb 2025), and Centers Plan for Healthy Living (NY Medicaid LTSS) all build out the services and home-care footprint. Source: [Motley Fool Q4 2025 transcript](https://www.fool.com/earnings/call-transcripts/2026/01/28/elevance-health-elv-q4-2025-earnings-transcript/), [Healthcare Finance](https://www.healthcarefinancenews.com/news/elevance-planning-carebridge-acquisition-estimated-27-billion).
Recent News Timeline
No Results
Page
/
2 15 of 25 records
What the Specialists Asked
Insider Spotlight
No Results
No Results
Institutional ownership
88.62
Insider ownership
2.72
Retail ownership
8.66
Vanguard stake
10.42
The ownership picture is conventional for a large-cap insurer: Vanguard, BlackRock, and State Street dominate; insider skin-in-the-game is modest at roughly $88M aggregate but the recent direction (a director's open-market buy and a $3.68M aggregate insider purchase total) is mildly bullish into the drawdown.
Industry Context
The web research is consistent on three sector-wide headwinds investors should keep in mind when reading ELV's numbers:
- Medicaid cost trend post-redetermination. All publicly traded MCOs — Centene, Molina, Humana, UnitedHealth, Elevance — flagged elevated medical costs in 2024–2025 driven by higher acuity in retained members. Elevance's Medicaid operating margin guidance for 2026 sits near negative 1.75%.
- Medicare Advantage repricing. UnitedHealth cut 2026 guidance and projected a revenue decline; Molina's stock fell 20% on a similar warning. Elevance's MA membership is projected to decline in the high-teens percent in 2026 by design (intentional bid pricing).
- ACA enrollment unwind. More than 1M fewer Americans signed up for Obamacare plans for 2026 as enhanced premium tax credits expired; Jefferies has been actively re-modeling Elevance's exchange-segment dynamics.
- AI as a battleground in claims. Reuters notes AI deployment "on both sides of the tug-of-war" between providers seeking higher reimbursement and insurers wanting proof of medical necessity. Elevance's Klover analysis paints AI/data as core to its competitive playbook.
Source: Reuters sector coverage, Klover.ai analysis.
All figures in USD. Cited dates reflect article publication or event timestamp as captured in the source URL. Where two sources differ on a metric, both are presented.